Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher, National University of Singapore Ink Life Sciences MOU

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific and the National University of Singapore today announced the signing of a memorandum of understanding to develop a strategic alliance to increase advance basic and applied research in Singapore.

The agreement covers the life sciences, healthcare, and applied markets, and includes cancer and diagnostics. Thermo Fisher and NUS will develop analytical technologies, reagents, instruments, and software, they said.

As part of the deal, Thermo Fisher will, for up to five years, sponsor short-term and multiyear research grants in the life sciences and will support collaborations with NUS, including a joint symposium to advance the exchange of scientific knowledge in the biological and physical sciences.

Financial and other details of the deal were not disclosed.

A year ago, the partners announced a collaboration with NUS' Environmental Research Institute to conduct metabolomic research into the water systems around Singapore.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.